fbpixel

Urinary Tract Infection research studies for holistic treatments

Around the world over thousands of years, patients have received root-cause holistic treatment for their diseases with personalized
treatment, diet and lifestyle modification recommendations. Read the inspiring true stories of practitioners who heal people and who recovered
from their problems after urinary-tract-infection treatment at their clinics. Many have been generous to share their knowledge and experience for the benefit
of other holistic experts and patients alike. Many practitioners share their Case Studies and the healing powers of urinary-tract-infection and related therapies
as they heal people who benefited from our expertise.

/ title=”Urinary bisphenol A and obesity NHANES 2003-2006″>
Urinary bisphenol A and obesity NHANES 2003-2006

August 2011

Background:
Bisphenol A (BPA) is a chemical suspected of causing endocrine and metabolic disruption in animals and humans. In rodents, in utero exposure to low-dose BPA is associated with weight gain. Detectable levels of BPA are found in most Americans due to its widespread use in the manufacture of food and drink packaging. We hypothesized that urinary BPA concentrations would be positively associated with general and central obesity.
METHODS:
Cross-sectional analysis of urinary BPA concentrations, body mass index, and waist circumference in 2747 adults (aged 18-74), using pooled data from the 2003/04 and 2005/06 National Health and diet therapy Examination Surveys.
Results:
The creatinine-adjusted geometric mean urinary BPA concentration was 2.05?g/g creatinine (25th percentile: 1.18, 75% percentile: 3.33). Relative to those in the lowest BPA quartile, participants in the upper BPA quartiles were more likely to be classified as obese (quartile 2 odds ratio (OR): 1.85, 95% confidence interval (CI): 1.22, 2.79; quartile 3 OR: 1.60, 95% CI: 1.05-2.44; quartile 4 OR: 1.76, 95% CI: 1.06-2.94). Higher BPA concentration was also associated with abdominal obesity (quartile 2 OR: 1.62, 95% CI: 1.11, 2.36; quartile 3 OR: 1.39, 95% CI: 1.02-1.90; quartile 4 OR: 1.58, 95% CI: 1.03-2.42). CONCLUSIONS: Higher BPA exposure is associated with general and central obesity in the general adult population of the United States. Reverse causation is of concern due to the cross-sectional nature of this study; longitudinal studies are needed to clarify the direction of the association.

/ onclick=”MoreLine(‘10951’, ‘Urinary bisphenol A and obesity NHANES 2003-2006’)”>
…more

/ title=”Association between urinary bisphenol A concentration and obesity prevalence in children and adolescents.”>
Association between urinary bisphenol A concentration and obesity prevalence in children and adolescents.

September 2012

CONTEXT: Bisphenol A (BPA), a manufactured chemical, is found in canned food, polycarbonate-bottled liquids, and other consumer products. In adults, elevated urinary BPA concentrations are associated with obesity and incident coronary artery . BPA exposure is plausibly linked to childhood obesity, but evidence is lacking to date. OBJECTIVE:
To examine associations between urinary BPA concentration and body mass outcomes in children. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional analysis of a nationally representative subsample of 2838 participants aged 6 through 19 years randomly selected for measurement of urinary BPA concentration in the 2003-2008 National Health and diet therapy Examination Surveys. MAIN OUTCOME MEASURES: Body mass index (BMI), converted to sex- and age-standardized z scores and used to classify participants as overweight (BMI?85th percentile for age/sex) or obese (BMI ?95th percentile).
Results:
Median urinary BPA concentration was 2.8 ng/mL (interquartile range, 1.5-5.6). Of the participants, 1047 (34.1% [SE, 1.5%]) were overweight and 590 (17.8% [SE, 1.3%]) were obese. Controlling for race/ethnicity, age, caregiver education, poverty to income ratio, sex, serum cotinine level, caloric intake, television watching, and urinary creatinine level, children in the lowest urinary BPA quartile had a lower estimated prevalence of obesity (10.3% [95% CI, 7.5%-13.1%]) than those in quartiles 2 (20.1% [95% CI, 14.5%-25.6%]), 3 (19.0% [95% CI, 13.7%-24.2%]), and 4 (22.3% [95% CI, 16.6%-27.9%]). Similar patterns of association were found in multivariable analyses examining the association between quartiled urinary BPA concentration and BMI z score and in analyses that examined the logarithm of urinary BPA concentration and the prevalence of obesity. Obesity was not associated with exposure to other environmental phenols commonly used in other consumer products, such as sunscreens and soaps. In stratified analysis, significant associations between urinary BPA concentrations and obesity were found among whites (P

/ onclick=”MoreLine(‘10950’, ‘Association between urinary bisphenol A concentration and obesity prevalence in children and adolescents.’)”>
…more

/ title=”A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.”>
A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.

October 2004

Background:
Recurrent urinary tract infections are a problem for many postmenopausal women. Estrogen replacement restores atrophic mucosa, lowers vaginal pH, and may prevent urinary tract infections.
METHODS:
We enrolled 93 postmenopausal women with a history of recurrent urinary tract infections in a randomized, double-blind, placebo-controlled trial of a topically applied intravaginal estriol cream. Midstream urine cultures were obtained at enrollment, monthly for eight months, and whenever urinary symptoms occurred. Vaginal cultures and pH measurements were obtained at entry and after one and eight months. The women were assigned to receive either estriol (n = 50) or placebo (n = 43), both administered intravaginally; 36 and 24, respectively, completed the eight months of follow-up.
Results:
The incidence of urinary tract infection in the group given estriol was significantly reduced as compared with that in the group given placebo (0.5 vs. 5.9 episodes per patient-year, P

/ onclick=”MoreLine(‘10886’, ‘A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.’)”>
…more

/ title=”Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women.”>
Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women.

June 1992

A block randomized, double-blind, group-comparative, placebo-controlled study was conducted to assess the effect of oestriol on recurrent urinary tract infections in postmenopausal women. 40 women, median age 78 years (66-91), 20 in each group, were treated with oestriol three mg p.o. per day or corresponding placebo for four weeks, followed by one mg per day for eight weeks. The main response parameter was the number of urinary tract infections per week in the two treatment periods. Both oestriol and placebo reduced the number of infections per week significantly in both periods, compared with the pretreatment period. There was no difference between oestriol and placebo treatment in the first period. In the second period, however, oestriol treatment was significantly more effective than placebo (p = 0.05). Correspondingly, there was a significant difference between the two groups in the vaginal pH at the end of the study (p less than 0.05). We conclude that oestriol reduces recurrent urinary tract infections in postmenopausal women.

/ onclick=”MoreLine(‘10885’, ‘Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women.’)”>
…more

/ title=”Relationship between Urinary Bisphenol A Levels and Diabetes Mellitus.”>
Relationship between Urinary Bisphenol A Levels and Diabetes Mellitus.

September 2011

Background:
Bisphenol A (BPA) is a widely used chemical in the manufacture of polycarbonate plastics and epoxy resins. Recent animal studies have suggested that BPA exposure may have a role in the development of weight gain, insulin resistance, pancreatic endocrine dysfunction, thyroid hormone disruption, and several other mechanisms involved in the development of diabetes. However, few human studies have examined the association between markers of BPA exposure and diabetes mellitus.
METHODS:
We examined the association between urinary BPA levels and diabetes mellitus in the National Health and diet therapyal Examination Survey (NHANES) 2003-2008. Urinary BPA levels were examined in quartiles. The main outcome of interest was diabetes mellitus defined according the latest American Diabetes Association guidelines.
Results:
Overall, we observed a positive association between increasing levels of urinary BPA and diabetes mellitus, independent of confounding factors such as age, gender, race/ethnicity, body mass index, and serum cholesterol levels. Compared to quartile 1 (referent), the multivariate-adjusted odds ratio (95% confidence interval) of diabetes associated with quartile 4 was 1.50 (1.05-2.14) (p-trend = 0.03). The association was present among normal-weight as well as overweight and obese subjects.Conclusions:Urinary BPA levels are found to be associated with diabetes mellitus independent of traditional diabetes risk factors. Future prospective studies are needed to confirm or disprove this finding.

/ onclick=”MoreLine(‘9348’, ‘Relationship between Urinary Bisphenol A Levels and Diabetes Mellitus.’)”>
…more

/ title=”Prevention of urinary tract infections with vitamin D supplementation”>
Prevention of urinary tract infections with vitamin D supplementation

June 2016

Background:
In observational studies vitamin D deficiency is associated with increased risk of infections, whereas the effect of vitamin D supplementation in randomized controlled trials is non-conclusive.
METHODS:
Five hundred and eleven subjects with prediabetes were randomized to vitamin D3 (20,000?IU per week) versus placebo for five years. Every sixth month, a questionnaire on respiratory tract infections (RTI) (common cold, bronchitis, influenza) and urinary tract infection (UTI) was filled in.
Results:
Mean baseline serum 25-hydroxyvitamin D (25(OH)D) level was 60?nmol/L. Two hundred and fifty-six subjects received vitamin D and 255 placebo. One hundred and sixteen subjects in the vitamin D and 111 in the placebo group completed the five-year study. Eighteen subjects in the vitamin D group and 34 subjects in the placebo group reported UTI during the study(p?

/ onclick=”MoreLine(‘9090’, ‘Prevention of urinary tract infections with vitamin D supplementation’)”>
…more

Have a Question?